Biofrontera Inc. - SIC # 3840 -

Ticker Exchange SIC # Website Latest Ticker
BFRI Nasdaq 3840 www.biofrontera-us.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Biofrontera Inc.

Biofrontera Inc. Announces Major Restructuring of Relationship With Biofrontera AG Backed By $11 Million Investment - Jun 30th, 2025 6:00 am
BIOFRONTERA INC. IS NEGOTIATING FUNDAMENTAL CHANGES TO ITS COOPERATION WITH BIOFRONTERA AG - Jun 11th, 2025 1:00 pm
Biofrontera Inc. Announces Patent for Propylene Glycol-Free Formula of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Now Listed in FDA Orange Book - Jun 3rd, 2025 12:30 pm
Biofrontera Inc (BFRI) Q1 2025 Earnings Call Highlights: Revenue Growth and Strategic ... - May 17th, 2025 1:03 am
Biofrontera Inc. Reports First Quarter 2025 Financial Results and Provides a Business Update - May 15th, 2025 3:09 pm
Biofrontera Inc. Announces New Patent Protection on Ameluz® until 2043 and the Completion of Patient Enrollment in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris - May 15th, 2025 10:17 am
Biofrontera Inc. to Report First Quarter FY 2025 Financial Results on May 15, 2025 - May 6th, 2025 10:45 am
Biofrontera and Almirall Launch the Hats On Challenge to Raise Awareness and Support for Actinic Keratosis - May 1st, 2025 12:38 pm
Biofrontera Full Year 2024 Earnings: Misses Expectations - Mar 22nd, 2025 8:06 am
Biofrontera Inc (BFRI) Q4 2024 Earnings Call Highlights: Record Revenue Growth Amidst Financial ... - Mar 22nd, 2025 1:01 am
Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update - Mar 21st, 2025 6:00 am
Biofrontera Inc. Announces Completion of Patient Enrollment in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Actinic Keratoses on the Extremities, Neck and Trunk - Mar 18th, 2025 7:30 am
Biofrontera Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 21, 2025 - Mar 11th, 2025 8:00 am
When Will Biofrontera Inc. (NASDAQ:BFRI) Turn A Profit? - Feb 22nd, 2025 5:57 am
Biofrontera Inc. Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC) - Jan 8th, 2025 7:50 am
Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market - Dec 23rd, 2024 7:30 am
Biofrontera Inc. to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference - Dec 3rd, 2024 9:00 am
Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note - Nov 22nd, 2024 7:10 am
Biofrontera Inc (BFRI) Q3 2024 Earnings Call Highlights: Strategic Advancements Amidst Revenue ... - Nov 15th, 2024 12:12 am
Biofrontera Inc. (BFRI) Reports Q3 Loss, Lags Revenue Estimates - Nov 13th, 2024 5:10 pm